Gilead granted conditional approval for Covid-19 treatment remdesivir in Europe

MARKET PULSE

Gilead Sciences, Inc. (gild) on Friday said the European Commission has granted conditional marketing authorization for remdesivir, also known as veklury, as a treatment for Covid-19. The authorization was based on a rolling review of supporting data that began in April 2020. Remdesivir is used to treat Covid-19 in adults and adolescents aged 12 years and older and weighing at least 40 kg, with pneumonia requiring supplemental oxygen. A European conditional marketing authorization is initially valid for one year but can be extended or turned into unlimited marketing authorization after the submission and assessment of additional confirmatory data.

sauce:https://www.msn.com/en-us/health/medical/gilead-granted-conditional-approval-for-covid-19-treatment-remdesivir-in-europe/ar-BB16iuLw

remdesiVOIR, nothing to see here…